Automated model-based testing based on an agnostic-platform modeling language

Currently multiple Domain Specific Languages (DSLs) are used for model-driven software development, in some specific domains. Software development methods, such as agile development, are test-centered, and their application in model-based frameworks requires model support for test development. We introduce a specific language to define generic test models, which can be automatically transformed into executable tests for particular testing platforms. The resulting test models represent the test plan for applications also built according to a model-based approach. The approach presented here includes some customisations for the application of the developed languages and transformation tools for some specific testing platforms. These languages and tools have been integrated with some specific DSL designed for software development

Road pollution estimation from vehicle tracking in surveillance videos by deep convolutional neural networks

Air quality and reduction of emissions in the transport sector are determinant factors in achieving a sustainable global climate. The monitoring of emissions in traffic routes can help to improve route planning and to design strategies that may make the pollution levels to be reduced. In this work, a method which detects the pollution levels of transport vehicles from the images of IP cameras by means of computer vision techniques and neural networks is proposed. Specifically, for each sequence of images, a homography is calculated to correct the camera perspective and determine the real distance for each pixel. Subsequently, the trajectory of each vehicle is computed by applying convolutional neural networks for object detection and tracking algorithms. Finally, the speed in each frame and the pollution emitted by each vehicle are determined. Experimental results on several datasets available in the literature support the feasibility and scalability of the system as an emission control strategy.This work is partially supported by the Ministry of Science, Innovation and Universities of Spain under grant RTI2018-094645-B-I00, roject name ‘‘Automated detection with low-cost hardware of unusual activities n video sequences’’. It is also partially supported by the Autonomous Government of Andalusia (Spain) under project UMA18-FEDERJA-084, project name ‘‘Detection of anomalous behavior agents by deep learning in low-cost video surveillance intelligent systems’’. All of them include funds from the European Regional Development Fund (ERDF). It is also partially supported by the University of Malaga (Spain) under grants B1-2019_01, project name ‘‘Anomaly detection on roads by moving cameras’’, and B1-2019_02, project name ‘‘Self-Organizing Neural Systems for Non-Stationary Environments’’. The authors thankfully acknowledge the computer resources, technical expertise and assistance provided by the SCBI (Supercomputing and Bioinformatics) center of the University of Málaga.thankfully acknowledge the computer resources, technical expertise and assistance provided by the SCBI (Supercomputing and Bioinformatics) center of the University of Málaga. They also gratefully acknowledge the support of NVIDIA Corporation with the donation of two Titan X GPUs. Finally, the authors thankfully acknowledge the grant of the Universidad de Málaga and the Instituto de Investigación Biomédica de Málaga - IBIMA. Funding for Open Access charge: University of Málaga/CBU

Análisis evolutivo económico-financiero de las empresas del servicio público de tranporte urbano en España. 2008-2013

El Observatorio de Costes y Financiación del Transporte Urbano Colectivo, desde su creación en noviembre de 2009, además de la realización de informes bianuales de la situación del sector español, ha realizado otros trabajos específicos en el sector del transporte en superficie ampliando año tras año la información a la que tiene acceso. En este sentido, y tras un acuerdo establecido con la Asociación del Transporte Urbano Colectivo, se ha elaborado un informe evolutivo del período 2008-2013. En la presente comunicación se muestran algunas de las conclusiones obtenidas al analizar una serie de elementos clave para observar las necesidades de financiación, la gestión competitiva y la correcta aplicación de los recursos por parte de las empresas gestoras de los transportes colectivos urbanos.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech

Tracking bluefin tuna cohorts from east Atlantic Spanish fisheries since the 1980s

Relative abundance and mean size at age analyses were performed for the catches of three Atlantic Spanish fisheries, in search of an exceptionally abundant cohort in the recent history of the eastern Atlantic and Mediterranean bluefin tuna stock. Length distributions of baitboat fisheries, both in the Bay of Biscay and areas close to the Strait of Gibraltar as well as trap catches from the Spanish Atlantic coast were converted to age distributions using age length keys from calcified structures. Results do validate indirectly the ageing method. The 1994 cohort was clearly tracked for juveniles and young adults, 3 to 7 years old, in baitboat catches, and also for older specimens, 9 to 11 years old, in the trap fisheries. Based on these results, it is suggested that the juvenile and young adults fisheries in the western part of the Iberian Peninsula are interconnected between one another and with the Balearic Islands area of the western Mediterranean, as it is the nearest spawning ground described and because it is also supported by tagging and other studies.Afin de trouver une cohorte exceptionnellement abondante dans la récente histoire du stock de ton rouge de l’Atlantique Est et de la Méditerranée, on a procédé à une analyse de l’abondance relative et de la taille moyenne par âge des captures réalisées par trois pêcheries espagnoles de l’Atlantique. Les distributions par tailles de deux pêcheries de canneurs dans le Golfe de Gascogne et dans les eaux proches du Détroit de Gibraltar, ainsi que les prises des madragues de la côte atlantique espagnole, ont été converties en âges à l’aide des clefs taille-âge obtenues à partir de la lecture de structures calcifiées. Les résultats valident indirectement la méthode de détermination de l’âge. La cohorte de 1994 affiche une forte indication présente chez les juvéniles et les jeunes adultes, de 3 à 7 ans, capturés dans les pêcheries de canneurs ainsi que chez les spécimens d’âge plus avancé, de 9 à 11 ans, pêchés à la madrague. Ces résultats suggèrent que les pêcheries de juvéniles et de jeunes adultes de la partie occidentale de la péninsule ibérique sont interconnectées entre elles ainsi qu’avec la zone des îles Baléares, en Méditerranée occidentale, étant donné qu’il s’agit de la zone de frai la plus proche et qu’il existe des indices de cette relation d’après les études de marquage et d’autres études.Para encontrar una cohorte excepcionalmente abundante en la historia reciente del stock de atún rojo del Atlántico este y Mediterráneo, se realizó un análisis de la abundancia relativa y la talla media por edad de las capturas de tres pesquerías atlánticas españolas. Las distribuciones de tallas de dos pesquerías de cebo vivo, en el Golfo de Vizcaya y en aguas próximas al Estrecho de Gibraltar, así como las capturas de las almadrabas de la costa atlántica española, fueron convertidas a edades mediante el uso de claves talla edad, obtenidas a partir de la lectura de piezas esqueléticas. Los resultados validan indirectamente el método de determinación de la edad. La cohorte de 1994 presenta una fuerte señal que pudo ser encontrada en los juveniles y adultos jóvenes, 3 a 7 años, capturados en las pesquerías de cebo vivo y también en especimenes mayores, 9 a 11 años, pescados con las almadrabas. Con esto resultados se sugiere que las pesquerías de juveniles y adultos jóvenes de la parte occidental de la península Ibérica están interconectadas entre ellas y con el área de las Islas Baleares, en el Mediterráneo occidental, puesto que es la zona de puesta más próxima y porque también hay evidencias de esta relación mediante el marcado y otros estudios

Long or complicated mpox in patients with uncontrolled HIV infection

To date, former research about the impact of HIV infection on mpox poor outcomes is still limited and controversial. Therefore, the aim of this study was to assess the impact of HIV on the clinical course of mpox, in a large population of patients from Spain. Nationwide case-series study. Patients from 18 Spanish hospitals, with PCR-confirmed mpox from April 27, 2022 to June 30, 2023 were included in this study. The main outcome was the development of long or complicated (LC) mpox, defined as: (i) duration of the clinical course ≥ 28 days, or; (ii) disseminated disease, or: (iii) emergence of severe complications. One thousand eight hundred twenty-three individuals were included. Seven hundred eighty-six (43%) were people living with HIV (PLWH), of whom 11 (1%) had a CD4 cell count < 200 cells/mm3 and 33 (3%) <350 cells/mm3 . HIV viral load ≥ 1000 cp/mL was found in 27 (3%) PLWH, none of them were on effective ART. Fifteen (60%) PLWH with HIV-RNA ≥ 1000 cp/mL showed LC versus 182 (29%) PLWH with plasma HIV-RNA load < 1000 copies/mL and 192 (24%) individuals without HIV infection (p < 0.001). In multivariate analysis, adjusted by age, sex, CD4 cell counts and HIV viral load at the time of mpox, only plasma HIV-RNA ≥ 1000 cp/mL was associated with a greater risk of developing LC mpox [adjusted OR = 4.06 (95% confidence interval 1.57-10.51), p = 0.004]. PLWH with uncontrolled HIV infection, due to lack of ART, are at a greater risk of developing LC mpox. Efforts should be made to ensure HIV testing is carried out in patients with mpox and to start ART without delay in those tested positive

IgA vasculitis: influence of CD40, BLK and BANK1 gene polymorphisms

CD40, BLK and BANK1 genes involved in the development and signaling of B-cells are identified as susceptibility loci for numerous inflammatory diseases. Accordingly, we assessed the potential influence of CD40, BLK and BANK1 on the pathogenesis of immunoglobulin-A vasculitis (IgAV), predominantly a B-lymphocyte inflammatory condition. Three genetic variants within CD40 (rs1883832, rs1535045, rs4813003) and BLK (rs2254546, rs2736340, rs2618476) as well as two BANK1 polymorphisms (rs10516487, rs3733197), previously associated with inflammatory diseases, were genotyped in 382 Caucasian patients with IgAV and 955 sex- and ethnically matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of CD40, BLK and BANK1 when IgAV patients and healthy controls were compared. Similar results were found when CD40, BLK and BANK1 genotypes or alleles frequencies were compared between patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Moreover, no CD40, BLK and BANK1 haplotype differences were disclosed between patients with IgAV and healthy controls and between patients with IgAV stratified according to the clinical characteristics mentioned above. Our findings indicate that CD40, BLK and BANK1 do not contribute to the genetic background of IgAV.Funding: This study was supported by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” (grants PI18/00042 and PI21/00042) from “Instituto de Salud Carlos III” (ISCIII, Health Ministry, Spain). D.P.-P. is a recipient of a Río Hortega program fellowship from the ISCIII, co-funded by the European Social Fund (ESF, “Investing in your future”) (grant number CM20/00006). F.G. is supported by funds of the RICORS Program from ISCIII, co-funded by the European Union (grant number RD21/0002/0025). V.P.-C. is supported by funds of PI18/00042. S.R.-M. is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). O.G. is a staff member of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and the European Union FEDER fund (grant numbers RD16/0012/0014 (RIER) and PI17/00409). He is a beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Program, project 734899—Olive-Net. R.L.-M. is a recipient of a Miguel Servet type II program fellowship from the ISCIII, co-funded by ESF (“Investing in your future”) (grant number CPII21/00004). Acknowledgments: We are indebted to the patients and healthy controls for their essential collaboration on this study. We also thank the National DNA Bank Repository (Salamanca) for supplying part of the control samples

Manejo de la inmunosupresión en pacientes trasplantados de riñón con COVID19. Estudio multicéntrico nacional derivado del registro COVID de la Sociedad Española de Nefrología

Introduction: SARS CoV2 infection has had a major impact on renal transplant patients with a high mortality in the first months of the pandemic. Intentional reduction of immunosuppressive therapy has been postulated as one of the cornerstone in the management of the infection in the absence of targeted antiviral treatment. This has been modified according to the patient`s clinical situation and its effect on renal function or anti-HLA antibodies in the medium term has not been evaluated.Objectives: Evaluate the management of immunosuppressive therapy made during SARS-CoV2 infection, as well as renal function and anti-HLA antibodies in kidney transplant patients 6 months after COVID19 diagnosis.Material and methods: Retrospective, national multicentre, retrospective study (30 centres) of kidney transplant recipients with COVID19 from 01/02/20 to 31/12/20. Clinical variables were collected from medical records and included in an anonymised database. SPSS statistical software was used for data analysis.Results: renal transplant recipients with COVID19 were included (62.6% male), with a mean age of 57.5 years. The predominant immunosuppressive treatment prior to COVID19 was triple therapy with prednisone, tacrolimus and mycophenolic acid (54.6%) followed by m-TOR inhibitor regimens (18.6%). After diagnosis of infection, mycophenolic acid was discontinued in 73.8% of patients, m-TOR inhibitor in 41.4%, tacrolimus in 10.5% and cyclosporin A in 10%. In turn, 26.9% received dexamethasone and 50.9% were started on or had their baseline prednisone dose increased. Mean creatinine before diagnosis of COVID19, at diagnosis and at 6 months was: 1.7 +/- 0.8, 2.1 +/- 1.2 and 1.8 +/- 1 mg/dl respectively (p < 0.001). 56.9% of the patients (N = 350) were monitored for anti-HLA antibodies. 94% (N = 329) had no anti-HLA changes, while 6% (N = 21) had positive anti-HLA antibodies. Among the patients with donor-specific antibodies post-COVID19 (N = 9), 7 patients (3.1%) had one immunosuppressant discontinued (5 patients had mycophenolic acid and 2 had tacrolimus), 1 patient had both immunosuppressants discontinued (3.4%) and 1 patient had no change in immunosuppression (1.1%), these differences were not significant.Conclusions: The management of immunosuppressive therapy after diagnosis of COVID19 was primarily based on discontinuation of mycophenolic acid with very discrete reductions or discontinuations of calcineurin inhibitors. This immunosuppression management did not influence renal function or changes in anti-HLA antibodies 6 months after diagnosis

Effectiveness of a strategy that uses educational games to implement clinical practice guidelines among Spanish residents of family and community medicine (e-EDUCAGUIA project):A clinical trial by clusters

This study was funded by the Fondo de Investigaciones Sanitarias FIS Grant Number PI11/0477 ISCIII.-REDISSEC Proyecto RD12/0001/0012 AND FEDER Funding.Background: Clinical practice guidelines (CPGs) have been developed with the aim of helping health professionals, patients, and caregivers make decisions about their health care, using the best available evidence. In many cases, incorporation of these recommendations into clinical practice also implies a need for changes in routine clinical practice. Using educational games as a strategy for implementing recommendations among health professionals has been demonstrated to be effective in some studies; however, evidence is still scarce. The primary objective of this study is to assess the effectiveness of a teaching strategy for the implementation of CPGs using educational games (e-learning EDUCAGUIA) to improve knowledge and skills related to clinical decision-making by residents in family medicine. The primary objective will be evaluated at 1 and 6months after the intervention. The secondary objectives are to identify barriers and facilitators for the use of guidelines by residents of family medicine and to describe the educational strategies used by Spanish teaching units of family and community medicine to encourage implementation of CPGs. Methods/design: We propose a multicenter clinical trial with randomized allocation by clusters of family and community medicine teaching units in Spain. The sample size will be 394 residents (197 in each group), with the teaching units as the randomization unit and the residents comprising the analysis unit. For the intervention, both groups will receive an initial 1-h session on clinical practice guideline use and the usual dissemination strategy by e-mail. The intervention group (e-learning EDUCAGUIA) strategy will consist of educational games with hypothetical clinical scenarios in a virtual environment. The primary outcome will be the score obtained by the residents on evaluation questionnaires for each clinical practice guideline. Other included variables will be the sociodemographic and training variables of the residents and the teaching unit characteristics. The statistical analysis will consist of a descriptive analysis of variables and a baseline comparison of both groups. For the primary outcome analysis, an average score comparison of hypothetical scenario questionnaires between the EDUCAGUIA intervention group and the control group will be performed at 1 and 6months post-intervention, using 95% confidence intervals. A linear multilevel regression will be used to adjust the model. Discussion: The identification of effective teaching strategies will facilitate the incorporation of available knowledge into clinical practice that could eventually improve patient outcomes. The inclusion of information technologies as teaching tools permits greater learning autonomy and allows deeper instructor participation in the monitoring and supervision of residents. The long-term impact of this strategy is unknown; however, because it is aimed at professionals undergoing training and it addresses prevalent health problems, a small effect can be of great relevance. Trial registration: ClinicalTrials.gov: NCT02210442.Publisher PDFPeer reviewe

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality